Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening

D

Desitin

Status

Completed

Conditions

Epilepsy

Treatments

Drug: sodium valproate

Study type

Observational

Funder types

Industry

Identifiers

NCT00870688
VPA 044/K

Details and patient eligibility

About

Valproate is the first line therapy in primary generalized seizures. The applied drug contains sodium valproate in sustained release minitablets. As a multiple unit dosage form these can be easily swallowed and taken independent from meals. A simple dosage scheme like valproate sustained release minitablets once daily in the evening should improve the compliance and likely the seizure situation of the patients. The data of this non interventional trial were directly extracted from the physician's electronic patient database. The observational period was 7 weeks compared to a retrospective period 7 weeks before start of the study.

Enrollment

82 patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age of 12 years and above
  • epilepsy patients
  • indication to initiation / conversion to valproate sustained release minitablets once daily

Exclusion criteria

  • contraindication to valproate use
  • no indication for conversion to valproate sustained release minitablets once daily

Trial design

82 participants in 1 patient group

1
Description:
epilepsy patients
Treatment:
Drug: sodium valproate

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems